The RHAPSODY Consortium

Leading European experts from 20 academic institutions, 5 EFPIA (European Federation of Pharmaceutical Industries and Associations) pharmaceutical organisations and two SMEs have collaborated closely in the Innovative Medicines Initiative (IMI) project RHAPSODY. IMI is a unique Public Private Partnership between the pharmaceutical industry (represented by the EFPIA) and the European Union. The RHAPSODY project has received funding of more than EUR 18 million through the IMI2 programme, which includes an EC contribution of around EUR 8 million, matching the dedicated resources provided by participating pharma companies, as well as funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).

RHAPSODY was a unique collaboration of leading public and private research groups, which has included over 100 researchers operating in 7 different scientific work packages. The RHAPSODY team was coordinated by the University of Lausanne, Servier and Lund University. RHAPSODY was based on the availability of large population prospective cohorts, with unique collection of genetic, biochemical and clinical data. RHAPSODY has also benefited from extensive and unique resources developed in previous IMI projects. Combining new and existing data with the expertise of its partners, RHAPSODY has developed novel biomarkers to refine diagnosis, leading to better patient stratification and with the aim of promoting diabetes prevention and supporting innovative drug discovery for personalized management of diabetes.
The RHAPSODY team is coordinated by the University of Lausanne, Servier and Lund University and is working on a new definition of the molecular taxonomy of T2D diabetes that will support patient segmentation, inform clinical trial design, and enable the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment.
Stacks Image 47
Stacks Image 398
Stacks Image 51
Stacks Image 349
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking ( under grant agreement No 115881. This Joint Undertaking has received support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work has been supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097-2.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.